- Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement.
- Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-? therapeutics.
- Legend Biotech was approved to launch its CAR-T therapy, Carvykti, in Europe for patients with multiple myeloma.
- Tianjin CanSino Biologics reported its novel recombinant coronavirus vaccine, Convidecia, was approved for Emergency Use by WHO.
For further details see:
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal